Chris Whitehouse, a political consultant and expert on medical technology policy and regulation at Whitehouse Communications, and advisor to MedTech suppliers assesses the positive implications for MedTech of a controversial decision to allow government to dictate the level of value thresholds adopted by a key regulator.
The UK government’s proposal to assume direct control over the cost-effectiveness thresholds used by medicines and MedTech value assessor, the National Institute for Health and Care Excellence (NICE), has sparked widespread debate. While much of the discussion has focused on pharmaceuticals, there are also potential consequences for medical devices. By shifting authority from NICE’s independent board to ministers, the move could reshape how innovative technologies, from diagnostic tools to surgical implants, are assessed, priced, and adopted within the NHS.
For over two decades, NICE has applied a cost-effectiveness threshold of £20,000 – £30,000 per quality-adjusted life year (QALY). This benchmark has guided decisions on whether treatments, including medical devices, deliver sufficient health benefit relative to their cost. The threshold is, arguably, long overdue for uplift and perhaps should be indexed in future for inflation.
Under the new arrangement, the threshold will rise to £25,000 – £35,000 per QALY. On the surface, this change may appear beneficial for device manufacturers, as higher thresholds increase the likelihood that their products will be deemed cost-effective. Devices that previously struggled to meet NICE’s strict criteria could now gain approval more easily.
But, there is concern in other quarters about the potential erosion of NICE’s independence. Traditionally, NICE has balanced clinical evidence, patient outcomes, and economic evaluation to ensure impartiality. Removing the requirement for consultation when thresholds are altered by ministerial direction could risk politicising the process. For medical devices, this could mean that greater weight in future is given to industrial policy objectives, such as attracting investment in the UK life sciences sector.
Medical device companies may welcome the higher thresholds, as they lower barriers to NHS adoption. Start-ups developing novel diagnostic technologies or implantable devices could find the UK market more accessible, encouraging innovation and investment.
Ultimately, the government’s intervention represents a trade-off: greater flexibility to align health policy with industrial strategy, but at the cost of NICE’s independence and methodological rigor. For medical devices, the impact will be twofold. On one hand, higher thresholds may stimulate innovation and broaden patient access to cutting-edge technologies. On the other, some are arguing, the politicisation of cost-effectiveness decisions could erode trust in the evaluation process, compromise patient safety, and destabilise the market environment.
As the consultation unfolds, stakeholders in the medical device sector – clinicians, patients, and industry leaders – must weigh these competing priorities. The challenge will be balancing economic ambitions with the fundamental goal of medical devices: delivering safe, effective, and value-driven care to patients.
MedTech developers and suppliers should engage with this consultation by completing the online survey which can be found here.
The Author used AI in preparing this article. Comments upon or questions about this article can be addressed to chris.whitehouse@whitehousecomms.com.
